Sökning: id:"swepub:oai:DiVA.org:uu-311474" >
Estrogen receptor b...
Estrogen receptor beta 1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
-
- Hasni, Muhammad Sharif (författare)
- Karolinska Institute
-
- Berglund, Mattias (författare)
- Karolinska Institutet,Karolinska Institute
-
- Yakimchuk, Konstantin (författare)
- Karolinska Institutet,Karolinska Institute
-
visa fler...
-
- Guan, Jiyu (författare)
- Karolinska Institute
-
- Linderoth, Johan (författare)
- Lund University,Lunds universitet,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,Lymphoma - Clinical Research,Lund University Research Groups,Skåne University Hospital
-
- Amini, Rose-Marie (författare)
- Uppsala University,Uppsala universitet,Klinisk och experimentell patologi,Rose-Marie Amini
-
- Enblad, Gunilla (författare)
- Uppsala University,Uppsala universitet,Experimentell och klinisk onkologi
-
- Okret, Sam (författare)
- Karolinska Institutet,Karolinska Institute
-
visa färre...
-
(creator_code:org_t)
- 2016-06-29
- 2017
- Engelska.
-
Ingår i: Leukemia and Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 58:2, s. 418-427
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is a favorable prognostic factor, which may be explained by estrogens. Here we show that when grafting human DLBCL cells to immunocompromised mice, tumor growth in males is faster. When treating mice grafted with either germinal center or activated B-cell like DLBCL cells with the selective estrogen receptor beta (ER beta) agonist diarylpropionitrile, tumor growth was significantly inhibited. Furthermore, nuclear ER beta 1 expression analysis in primary DLBCL's by immunohistochemistry revealed expression in 89% of the cases. Nuclear ERb1 expression was in a univariate and multivariate analysis, an independent prognostic factor for adverse progression-free survival in Rituximab-chemotherapy treated DLBCL (p = 0.02 and p = 0.04, respectively). These results suggest that estrogen signaling through ERb1 is an interesting future therapeutic target for treatment of DLBCL, and that ERb1 expression can be used as a prognostic marker.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)
Nyckelord
- Estrogen
- gender difference
- immunohistochemistry
- lymphoma growth
- receptor expression
- Patologi
- Pathology
- Estrogen
- gender difference
- immunohistochemistry
- lymphoma growth
- receptor expression
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas